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Multisite Imaging to Predict Multiple Outcomes*Michael J. Blaha, MD, MPHD espite decades of observations establishingatherosclerosis as a systemic disease asso-ciated with multiple adverse outcomes,
most risk assessment tools are designed to predict
just one atherosclerosis-related condition: coronary
heart disease (CHD). Thus, the most notable change
in the new American College of Cardiology/American
Heart Association (ACC/AHA) Risk Assessment
Guidelines is the inclusion of stroke as a co-primary
outcome (1).
What are the implications of modeling a broader
set of cardiovascular diseases? From one perspective,
this shift toward the more inclusive endpoint of
atherosclerotic cardiovascular disease (ASCVD) is a
welcome change, as stroke is common, frequently
preventable, and associated with marked morbidity
and mortality. However, from the perspective of risk
prediction, inclusion of a disparate and heteroge-
neous outcome like stroke reduces the speciﬁcity
of the prediction tool (2). How does one maintain
highly personalized risk estimates while simulta-
neously considering multiple different cardiovascular
outcomes?
RISK PREDICTION HYPOTHESIS 1. It is likely impos-
sible for a simple equation using 1-time measures of
traditional risk factors (such as the Framingham Risk
Score or the new Pooled Cohort Equations) to capture
the complexity of atherosclerosis as a systemic disease.
There has been contentious debate over the per-
ceived level of personalization in the new ACC/AHA
prevention guidelines. Despite some advances in
the long-awaited Pooled Cohort Equations Risk Esti-
mator, such as separate equations for African*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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algorithm incorporates the same traditional risk fac-
tors as the original Framingham Risk Score published
in 1998 (age, sex, race, systolic blood pressure,
smoking, diabetes, total and high-density lipoprotein
cholesterol). Chronological age of the patient, now
more than ever, is the dominant factor in deter-
mining risk. Thus, while the new guidelines have
expanded the scope of outcomes, the scope of the
risk factors has not changed in over 25 years. This
presents distinct challenges for multi-outcome risk
prediction because the age and risk factor de-
terminants differ for CHD and stroke (for example,
cholesterol is important for CHD but less so for
stroke, whereas the reverse is true for hypertension).
As a result, it remains unclear whether the shift to-
ward a single risk model incorporating a composite
outcome leads to more personalized—or potentially
less personalized—risk assessment (3).
Personalization of risk has long been considered
the primary advantage of imaging (4). Traditional risk
factors are limited by their reﬂection of a biological
state at a single point in time (for example, blood
pressure of a patient at one moment during a
clinical encounter). In contrast, by integrating the
lifetime exposure to both measured and unmeasured
risk factors, atherosclerosis imaging allows direct
visualization of the cumulative effect of all risk
determinants in an individual patient in the vascular
bed of interest. As such, imaging appears better suited
to reﬂect the complex biological interaction networks
and multiorgan crosstalk that underpins the remark-
ably complex pathogenesis of atherosclerosis as a
systemic disease.
RISK PREDICTION HYPOTHESIS 2. The best way to
predict a particular ASCVD outcome is to directly im-
age the vascular bed of interest.
It is now well-known that coronary artery calcium
(CAC) scoring is a powerful predictor of CHD that adds
substantial predictive power to conventional risk
scoring (5). CAC not only identiﬁes those at high risk
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1055of CHD (6), but also those at very low risk of the
development of CHD (7) and thus can be used to
facilitate personalized decision making when
deciding whether to treat with aspirin or a statin (4).
CAC receives a class IIB recommendation in the new
guidelines for patients in whom “the decision to treat
with a statin is unclear” (1), although frustratingly the
optimal interpretation of this phrase remains equally
“unclear.”SEE PAGES 1025 AND 1039However, despite the power of CAC in predicting
CHD, CAC is less effective for the prediction of stroke.
In fact, measurements of carotid intima-media
thickness, carotid plaque, and possibly aortic and/or
intracranial carotid calciﬁcation may predict stroke
better than CAC (8,9). In this issue of iJACC, Naqvi
et al. (10) provide a wonderful review and critique
of the current state of carotid ultrasound and
the potential for various techniques including
3-dimensional ultrasound to improve risk prediction,
particularly for stroke. Therefore, if the goal is to
predict CHD, CAC is likely the optimal imaging test.
However, if the goal is to predict stroke, incorporating
imaging of the carotid or the thoracic aorta may be
superior. Likewise, the optimal approach may vary
further if the goal is to predict heart failure, periph-
eral vascular disease, or ASCVD-related death. As our
understanding of the implications of atherosclerosis
broadens, new outcomes will need to be modeled.
Also in this issue of iJACC, Friedman et al. (11) discuss
the role of identifying early abnormalities on brain
imaging. Perhaps brain imaging will be the best way
to anticipate the important outcome of vascular
dementia.
RISK PREDICTION HYPOTHESIS 3. Disease-speciﬁc,
empirically derived combinations of multisite imaging
measures will improve prediction across the spectrum
of ASCVD outcomes.
Multisite imaging studies have opened our eyes
to the remarkable heterogeneity in atherosclerosis
across multiple vascular beds. For example, Wong
et al. (12) used data from the MESA (Multi-Ethnic
Study of Atherosclerosis) to show that w30% of
individuals with abdominal aortic calcium (AAC) do
not have CAC, whereas >30% of individuals without
AAC have abnormalities in another vascular bed.
Similarly, studies have shown distinct risk factor
patterns for disease in each vascular territory (for
example, CAC is more associated with dyslipidemia
and male sex, whereas AAC is more associated with
smoking with equal association with female sex)
(13). Multiple studies have now shown thatalthough CAC predicts CHD and ASCVD events, AAC
is more predictive of cardiovascular and all-cause
death (14).
With the shift toward a multiple outcome (i.e.,
systems-based) approach to cardiovascular risk
assessment, how can we leverage this heterogeneity
for improving risk prediction? First of all, future
multisite imaging studies must shift toward closely
examining the heterogeneity in atherosclerosis rather
than simply reporting concordance across measures.
Reports stressing concordance of atherosclerosis
measure 1 to measure 2 are extremely common and
are probably less helpful. From an epidemiological
perspective, the degree of heterogeneity is the
most critical determinant of incremental risk predic-
tion (15).
More importantly, future studies should look to
derive disease-speciﬁc combinations of imaging
measures aimed at predicting particular cardiovas-
cular outcomes (15). The weighting of each factor
should be empirically derived from the relative
risk observed in well-designed prospective studies
like MESA. For example, on a noncontrast cardiac
computed tomography scan, a combination of CAC
and thoracic aorta calcium may best predict CHD.
A combination of mitral annular calcium, aortic
valve calcium, and thoracic aorta calcium may best
predict stroke. CAC plus 3-dimensional ultrasound
for carotid plaque assessment may be the most
parsimonious combination to address the new ACC/
AHA guidelines outcome of CHD þ stroke (ASCVD).
The ideal combination of imaging measures for
predicting heart failure, peripheral vascular dis-
ease, and vascular dementia is almost completely
unknown.
What are the challenges to successful imple-
mentation of multisite imaging? The ﬁrst is cost. The
second is radiation. Combining noncontrast CTs of
the brain, neck, chest, and abdomen may markedly
increase mean radiation dose, although this could be
mitigated by combining CT with ultrasound. Third is
patient selection. Who is the ideal patient to undergo
multisite imaging? Clearly the yield would be low in
both young patients and elderly patients and unlikely
to change clinical management in very low risk pa-
tients or very high risk patients. The ﬁnal problem is
incidental ﬁndings. Incidental pulmonary nodules are
already a barrier to more widespread appropriate use
of CAC. Until there is consensus about the clinical
value of following low-risk incidental ﬁndings,
multisite imaging will not withstand rigorous cost-
effectiveness analysis.
In conclusion, the future is bright for using
multisite imaging to improve multioutcome risk
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1056prediction. At present, the new Pooled Risk Equations
represent a useful starting point to the clinical risk
discussion. However, many would agree that the
future of risk prediction will include the upfront use
of imaging. Based on the cumulative results from a
variety of imaging studies—spanning vascular beds
and imaging modalities—now may be the time for usto initiate a complete rethinking of the conventional
approach to risk prediction.
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